Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors. Proceeds from the sale will go to the selling shareholders.
Motilal Oswal initiates coverage on Adani Enterprises with Buy, sees 25% upside. Here’s why
Motilal Oswal has initiated coverage on Adani Enterprises with a Buy rating and a target price of Rs 3,880, implying 25% upside from the prevailing